Vanguard Capital Management
CLPT icon

Vanguard Capital Management’s ClearPoint Neuro CLPT Stock Holding History

Vanguard Capital Management’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22M Sell
1,232,807
-10,808
-0.9% -$135K ﹤0.01% 2395
2026
Q1 		$11.3M Buy
+1,243,615
New +$15.7M ﹤0.01% 2664

Other funds holding CLPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
CFM
Compass Financial Management Tampa, Florida $829M AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vanguard Capital Management's CLPT Position: Q2 2026 in Review

Vanguard Capital Management reduced its ClearPoint Neuro (CLPT) stake by 0.87% in Q2 2026, selling an estimated $135K and leaving 1,232,807 shares worth $22M. The position accounts for ﹤0.01% of the portfolio, ranked #2395.

Vanguard Capital Management first reported a position in CLPT in Q1 2026 and has held it in 2 quarters since. 129 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

  • Vanguard Capital Management held 1,232,807 shares of ClearPoint Neuro worth $22M as of Q2 2026.
  • Vanguard Capital Management sold 10,808 ClearPoint Neuro shares in Q2 2026, an estimated $135K.
  • ClearPoint Neuro made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2395 holding.
  • Vanguard Capital Management first reported a position in ClearPoint Neuro in Q1 2026 and has held it in 2 quarters since.
  • 129 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.